PepGen (NASDAQ:PEPG) Rises on Promising Phase 1 DMD Trial Data
Market News

PepGen (NASDAQ:PEPG) Rises on Promising Phase 1 DMD Trial Data

Shares of biotechnology company PepGen (NASDAQ:PEPG) are up in the pre-market session today after its lead candidate PGN-ED051 demonstrated promising results in a Phase 1 trial for treating Duchenne Muscular Dystrophy (DMD).

The drug showed high oligonucleotide delivery and exon skipping and was generally well tolerated. The company now plans to begin a Phase 2a trial in the first half of 2023.

Is PEPG Stock a Buy?

Analysts currently have a Strong Buy consensus rating on PEPG stock with an average price target of $27 which indicates a massive 227.27% potential upside for PepGen Stock.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles